the aid library

Filter

8512

Best practice guidelines for mental health promotion programs: Refugees

Centre for Addiction and Mental Health (CAMH); Dalla Lana School of Public Health, University of Toronto; Toronto Public Health (2012) C1

This resource is the third in a series of online guides for promoting positive mental health across the lifespan. This resource provides health and social service providers (“practitioners”) with current evidence-based approaches in the application of mental health promotion concepts and princip ... more

HIV/AIDS surveillance in Europe 2017

A. Pharris; A. Stengaard World Health Organization (Europe); European Centre for Disease Prevention and Control (2017) C_WHO

2016 data The report was coordinated by Anastasia Pharris and Annemarie Stengaard. Report review and production support were provided by Andrew J. Amato-Gauci, Mike Catchpole, Denis Coulombier, Masoud Dara, Nedret Emiroglu, Rachel Katterl, Shahin Khasiyev, Valentina Lazdina, Teymur Noori, Marc ... more

Poblaciones Urbanas

Stop TB Partnership; UNOPS; END TB (2017) C1

Informe sobre poblaciones clave Accessed November 2017

ACTUALIZACIÓN COVID-19

Ferres M., Potin M. (2020) C2

El presente material es un aporte NO OFICIAL y volutario realizado a partir de la reunión clínica del equipo de Infectología Pediátrica PUC. Su objetivo de aportar con un recurso educativo que contribuya a la actualización de los profesionales y estudiantes de la salud respecto a este problem ... more

Primeiros Cuidados Psicológicos:guia para trabalhadores de campo
recommended

Organização Mundial da Saúde, World Trauma Foundation, World Vision (2011) C_WHO

Sudan: Multi-Year Humanitarian Strategy 2017-2019

UN Office for the Coordination of Humanitarian Affairs (2017) C1

Spousal Violence and HIV: Exploring the Linkages in Five Sub-Saharan African Countries

MacQuarrie, Kerry L.D., Rebecca Winter, and Sunita Kishor ICF International (2013) C2

DHS Analytical Studies No. 36

WHO global report on trends in prevalence of tobacco use 2000-2025

World Health Organization WHO (2021) C_WHO

Progress in reducing tobacco use is a key indicator for measuring countries’ efforts to implement the WHO Framework Convention on Tobacco Control – target 3.a under the Sustainable Development Goals agenda. Countries have adopted this indicator to report progress also towards the tobacco reducti ... more

The path that ends AIDS: UNAIDS Global AIDS Update 2023
recommended

UN Children's Fund UNICEF (2023) CC

This report makes clear that there is a path to end AIDS. Taking that path will help ensure preparedness to address other pandemic challenges, and advance progress across the Sustainable Development Goals. The data and real-world examples in the report make it very clear what that path is. It is not ... more

Global vaccine safety blueprint 2.0 (GVSB2.0) 2021-2023

World Health Organization WHO (2022) C_WHO

Rapport mondial 2020 : Agissons maintenant - Pour combattre les profondes inégalités et mettre fin aux pandémies
recommended

ONUSIDA (2020) C_WHO

Objectifs 2020 : des avancées disparates. Le rapport de l’ONUSIDA sur l’épidémie mondiale de sida fait état d’un échec accentué par la COVID-19. Depuis 2015, 3,5 millions d’infections au VIH et 820 000 morts supplémentaires liés au sida sont imputables à des objectifs non atteints. ... more

Independent Monitoring Board of the Global Polio Eradication Initiative (Fifteenth Report: December 2017)

Global Polio Eradication Initiative (2017) C1

The report reviews progress with the task of planning and implementing measures necessary to secure a completely polio-free world. It also examines actions aimed at ensuring successful transfer of polio assets, innovations developed and lessons learned to countries’ public health programmes and ot ... more

Trastorno por déficit de atención con hiperactividad

T. S. Moriyama; A. J. M. Cho; R. E. Verin; et al. IACAPAP (2017) C2

Trastornos externalizantes Capítulo D.1 Edición: Matías Irarrázaval & Andrés Martín Traducción: Fernanda Prieto Tagle, Marta García Acuña

National Guidelines for Integrated Diseases Surveillance and Response Uganda

World Health Organization WHO, Regional Office of Africa; Ministry of Health Uganda (2021) C_WHO

3rd edition. In 2001, Uganda adapted the Integrated Disease Surveillance and Response (IDSR) developed by World Health Organization (WHO) for member states in African region. The Ministry of Health has been implementing the IDSR strategy since then with success across the country. This strategy prov ... more

The Global State of Harm Reduction 2016

K. Stone; G. Sander Harm Reduction International (2016) C2

Guide to introducing human rabies vaccine into national immunization programmes: Handbook

World Health Organization World Health Organization WHO (2022) C_WHO

Rabies is fatal, vaccine-preventable disease responsible for an estimated 59,000 human deaths each year. Most cases are transmitted by dogs, and most deaths occur in underserved populations in Africa and Asia. Approximately 40% of deaths occur in children.

Adolescent Girls in Disaster & Conflict: Interventions for Improving Access to Sexual and Reproductive Health Services

S. Guthridge-Gould UNFPA (United Nations Population Fund) (2016) C2

Basic Epidemiology

Bonita, R.; R.Beaglehole, and T. Kjellström World Health Organization WHO (2006) C_WHO

2nd edition

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Global clinical data platform for severe acute hepatitis of unknown aetiology in children case report form (CRF)

World Health Organization WHO (2022) C_WHO

Multiple countries are reporting severe acute cases of hepatitis of unknown aetiology in children, in several regions of the world. WHO has developed this clinical case report form (CRF) to support and facilitate reporting of anonymized, patient-level data of acute hepatitis of unknown aetiology.